We are live on
!
Find out more
HR
Howe & Rusling Portfolio holdings
AUM
$1.72B
1-Year Est. Return
25.63%
This Fund
S&P 500
This Quarter
Est. Return
+2.29%
1 Year Est. Return
+25.63%
3 Year Est. Return
+82.02%
5 Year Est. Return
+99.95%
10 Year Est. Return
+300.08%
AUM
$1.51B
AUM Growth
+$53.2M
(+3.6%)
Cap. Flow
+$28.6M
Cap. Flow
% of AUM
1.89%
Top 10 Holdings %
Top 10 Hldgs %
32.89%
Holding
512
New
60
Increased
196
Reduced
114
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard High Dividend Yield ETF
VYM
|
+$7.79M |
| 2 |
Honeywell
HON
|
+$4.05M |
| 3 |
S&P Global
SPGI
|
+$4.01M |
| 4 |
Intercontinental Exchange
ICE
|
+$3.89M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regal Rexnord
RRX
|
+$9.61M |
| 2 |
AstraZeneca
AZN
|
+$9.02M |
| 3 |
FISV
Fiserv Inc
FISV
|
+$5.57M |
| 4 |
Amdocs
DOX
|
+$5M |
| 5 |
Broadcom
AVGO
|
+$4.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 32.75% |
| 2 | Technology | 18.94% |
| 3 | Financials | 11.97% |
| 4 | Consumer Discretionary | 7.09% |
| 5 | Healthcare | 6.84% |
Similar funds
PIMG
SIM
NHAS
AFG
FDCP
PP
GAM
TLFA
Howe & Rusling's Q4 2025 Portfolio in Review
As of Q4 2025, Howe & Rusling held 512 positions worth $1.51B, up 3.6% from $1.46B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Howe & Rusling's Q4 2025 filing shows 60 new, 196 increased, 114 reduced and 31 closed positions. Its largest new stake was Solstice Advanced Materials: 11,204 shares worth $544K. The largest sale was Regal Rexnord, an estimated $9.61M.
By sector, the portfolio is most concentrated in Miscellaneous at 33% of assets, up from 31% a quarter earlier, followed by Technology and Financials.
- Howe & Rusling's largest Q4 2025 buy was Solstice Advanced Materials: 11,204 shares worth $544K.
- Howe & Rusling added most to Vanguard High Dividend Yield ETF in Q4 2025, an estimated $7.79M increase.
- Howe & Rusling's biggest Q4 2025 reduction was Regal Rexnord, cutting an estimated $9.61M.
- Howe & Rusling fully exited AstraZeneca in Q4 2025, selling an estimated $9.02M.
- Howe & Rusling's ten largest holdings make up 33% of its $1.51B portfolio in Q4 2025.
- Howe & Rusling opened 60 new positions and closed 31 in Q4 2025.
- Howe & Rusling's portfolio value rose 3.6% quarter-over-quarter to $1.51B.
Based on Howe & Rusling's 13F filing for Q4 2025, filed 17 Feb 2026.